ANAB

AnaptysBio, Inc. NASDAQ Listed Jan 26, 2017

Healthcare ·Biotechnology ·US · anaptysbio.com

$67.36

After hrs $67.36 +0.00%

Mkt Cap $2.9B

52w Low $11.40 91.8% of range 52w High $72.36

50d MA $46.00 200d MA $29.34

P/E (TTM) -145.1x

EV/EBITDA 13.4x

P/B 49.9x

Debt/Equity 0.4x

ROE -35.6%

P/FCF 45.8x

RSI (14) —

ATR (14) —

Beta 0.41

50d MA $46.00

200d MA $29.34

Avg Volume 863.4K

About

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 3, 2026	AMC	0.89	1.58	+77.5%	35.22	+6.2%	+14.6%	+8.4%	+4.9%	+13.0%	+17.4%	—
Nov 4, 2025	AMC	-1.06	0.52	+149.1%	23.16	+12.9%	+3.6%	+10.0%	+14.1%	-2.2%	-3.4%	—
Aug 7, 2025	AMC	-1.50	-1.34	+10.7%	13.58	+1.8%	+3.2%	-1.8%	-1.3%	+1.7%	-2.0%	—
May 5, 2025	AMC	-1.30	-1.28	+1.5%	13.82	+2.2%	-3.0%	-5.1%	-5.6%	-5.5%	-3.4%	—
Feb 27, 2025	AMC	-1.55	-0.72	+53.5%	10.93	+18.7%	+2.6%	-10.7%	-7.0%	+2.2%	+0.0%	—
Nov 5, 2024	AMC	-1.72	-1.14	+33.7%	13.25	+11.8%	+11.8%	+8.2%	+7.2%	+12.7%	+8.2%	—
Aug 5, 2024	AMC	-1.20	-1.71	-42.5%	21.58	+4.0%	-0.9%	-2.5%	+3.8%	+2.1%	+4.3%	—
May 9, 2024	AMC	-1.54	-1.64	-6.5%	17.49	-0.3%	-10.7%	-8.6%	-3.7%	-2.4%	-2.9%	—
Mar 12, 2024	AMC	-1.60	-1.59	+0.7%	17.37	-0.3%	-5.2%	-9.4%	-10.0%	-11.1%	-10.7%	—
Nov 2, 2023	AMC	-1.72	-1.41	+18.0%	10.80	+8.9%	+8.2%	+2.9%	+1.9%	-4.4%	-8.0%	—
Aug 7, 2023	AMC	-1.70	-1.50	+11.5%	12.31	+3.2%	+2.6%	-4.2%	-2.1%	+2.9%	+4.4%	—
May 11, 2023	AMC	-1.04	-1.58	-51.9%	13.84	-0.1%	-6.3%	-6.7%	-10.3%	-8.2%	-8.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 28	Leerink Partners	Maintains	Outperform → Outperform	—	$66.59	$67.16	+0.9%	-0.7%	-6.4%	-1.3%	+0.3%	—
Apr 22	Barclays	Maintains	Overweight → Overweight	—	$51.82	$51.56	-0.5%	+3.3%	-1.1%	+13.6%	+28.5%	+27.6%
Apr 21	UBS	Maintains	Buy → Buy	—	$50.95	$51.08	+0.3%	+1.7%	+5.1%	+0.6%	+15.6%	+30.7%
Mar 31	Piper Sandler	Maintains	Overweight → Overweight	—	$36.92	$38.33	+3.8%	+0.1%	+2.4%	+4.1%	+12.7%	+12.2%
Mar 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$38.26	$38.03	-0.6%	-3.5%	-3.4%	-1.2%	+0.5%	+8.8%
Mar 17	UBS	Maintains	Buy → Buy	—	$43.19	$43.37	+0.4%	+3.9%	-0.1%	-0.1%	-3.7%	-3.2%
Mar 12	Wedbush	Maintains	Outperform → Outperform	—	$43.11	$43.12	+0.0%	-1.3%	+0.2%	+0.2%	+4.1%	+0.1%
Mar 9	Truist	Maintains	Hold → Hold	—	$36.94	$36.88	-0.2%	+7.7%	+11.9%	+16.7%	+15.1%	+17.0%
Mar 5	Stifel	Maintains	Buy → Buy	—	$40.37	$39.67	-1.7%	-5.4%	-8.5%	-1.4%	+2.4%	+6.8%
Mar 4	Barclays	Maintains	Overweight → Overweight	—	$35.22	$37.39	+6.2%	+14.6%	+8.4%	+4.9%	+13.0%	+17.4%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$35.22	$37.39	+6.2%	+14.6%	+8.4%	+4.9%	+13.0%	+17.4%
Jan 20	Barclays	Maintains	Overweight → Overweight	—	$30.45	$30.00	-1.5%	+1.2%	+2.2%	+3.6%	+4.1%	+3.2%
Dec 17	Barclays	Maintains	Overweight → Overweight	—	$30.02	$29.65	-1.2%	+1.5%	+5.6%	+9.0%	+11.8%	+11.1%
Dec 11	Stifel	Maintains	Buy → Buy	—	$29.97	$29.71	-0.9%	+1.8%	-0.0%	+1.3%	+0.2%	+1.6%
Nov 24	Wedbush	Maintains	Outperform → Outperform	—	$26.41	$26.49	+0.3%	+5.9%	+4.8%	+6.4%	+5.1%	+4.3%
Nov 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.41	$26.49	+0.3%	+5.9%	+4.8%	+6.4%	+5.1%	+4.3%
Nov 11	Barclays	Maintains	Overweight → Overweight	—	$22.65	$22.02	-2.8%	-1.2%	-2.6%	-2.1%	-0.4%	+2.3%
Nov 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.65	$22.02	-2.8%	-1.2%	-2.6%	-2.1%	-0.4%	+2.3%
Nov 10	Truist	Maintains	Hold → Hold	—	$26.43	$21.33	-19.3%	-14.3%	-15.4%	-16.5%	-16.1%	-14.7%
Nov 5	Wells Fargo	Maintains	Overweight → Overweight	—	$23.16	$26.15	+12.9%	+3.6%	+10.0%	+14.1%	-2.2%	-3.4%
Nov 5	Guggenheim	Maintains	Buy → Buy	—	$23.16	$26.15	+12.9%	+3.6%	+10.0%	+14.1%	-2.2%	-3.4%
Oct 29	Stifel	Maintains	Buy → Buy	—	$24.11	$25.27	+4.8%	-0.1%	+0.8%	+1.2%	-0.3%	-3.9%
Oct 15	Wedbush	Maintains	Outperform → Outperform	—	$21.23	$21.03	-0.9%	+7.7%	+8.0%	+8.8%	+10.8%	+7.1%
Sep 30	Wedbush	Maintains	Outperform → Outperform	—	$15.51	$17.11	+10.3%	+31.6%	+37.4%	+34.7%	+33.0%	+30.0%
Sep 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.51	$17.11	+10.3%	+31.6%	+37.4%	+34.7%	+33.0%	+30.0%
Aug 12	UBS	Maintains	Neutral → Neutral	—	$13.33	$13.31	-0.1%	+0.6%	+3.6%	-0.1%	+0.8%	+0.1%
Aug 7	Wedbush	Maintains	Outperform → Outperform	—	$15.03	$15.71	+4.5%	-9.6%	-6.7%	-11.3%	-10.8%	-8.1%
Jul 24	JP Morgan	Maintains	Overweight → Overweight	—	$18.00	$18.77	+4.3%	-0.1%	-0.2%	-1.5%	-2.9%	-7.5%
Jun 4	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$15.68	$16.43	+4.8%	-9.6%	-10.1%	+0.8%	-1.4%	+1.9%
May 28	Guggenheim	Maintains	Buy → Buy	—	$13.42	$14.09	+5.0%	+3.8%	+12.1%	+10.4%	+8.6%	+16.8%
May 6	Guggenheim	Maintains	Buy → Buy	—	$13.82	$14.13	+2.2%	-3.0%	-5.1%	-5.6%	-5.5%	-3.4%
May 1	Wedbush	Maintains	Outperform → Outperform	—	$14.81	$14.76	-0.3%	-2.3%	-4.6%	-6.7%	-9.5%	-11.4%
Mar 5	JP Morgan	Maintains	Overweight → Overweight	—	$10.17	$10.23	+0.6%	+9.8%	+7.5%	+7.1%	+9.6%	+14.9%
Mar 4	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$9.76	$9.63	-1.3%	+4.2%	+14.4%	+12.0%	+11.6%	+14.2%
Feb 13	Wells Fargo	Maintains	Overweight → Overweight	—	$10.77	$11.08	+2.9%	+19.4%	+31.4%	+22.5%	+21.4%	+16.8%
Feb 12	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$8.25	$8.37	+1.5%	+30.5%	+55.9%	+71.5%	+59.9%	+58.4%
Feb 7	Wedbush	Maintains	Outperform → Outperform	—	$10.72	$10.73	+0.1%	-9.3%	-19.1%	-23.0%	+0.5%	+20.0%
Feb 4	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$11.11	$11.63	+4.7%	-0.9%	-3.6%	-3.5%	-12.5%	-22.0%
Dec 19	JP Morgan	Maintains	Overweight → Overweight	—	$10.23	$10.10	-1.3%	-2.2%	-5.2%	-9.0%	-9.5%	-10.5%
Dec 18	Truist	Maintains	Hold → Hold	—	$10.66	$10.97	+2.9%	-4.0%	-6.2%	-9.0%	-12.7%	-13.1%
Dec 12	Guggenheim	Maintains	Buy → Buy	—	$10.34	$10.39	+0.5%	-3.2%	+0.5%	+7.4%	+3.1%	-1.1%
Dec 12	Wells Fargo	Maintains	Overweight → Overweight	—	$10.34	$10.39	+0.5%	-3.2%	+0.5%	+7.4%	+3.1%	-1.1%
Dec 11	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$15.39	$9.55	-37.9%	-32.8%	-35.0%	-32.5%	-27.9%	-30.7%
Dec 2	BTIG	Downgrade	Buy → Neutral	—	$16.64	$15.68	-5.8%	-2.3%	-11.8%	-3.5%	-5.2%	-0.6%
Nov 12	JP Morgan	Maintains	Overweight → Overweight	—	$14.93	$14.57	-2.4%	-4.0%	-7.4%	-9.9%	-15.1%	-15.7%
Nov 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.25	$14.81	+11.8%	+11.8%	+8.2%	+7.2%	+12.7%	+8.2%
Oct 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.79	$14.71	-0.5%	-2.5%	-2.3%	-10.1%	-10.4%	+0.1%
Oct 30	UBS	Maintains	Neutral → Neutral	—	$20.53	$15.33	-25.3%	-28.0%	-29.8%	-29.6%	-35.3%	-35.5%
Oct 21	Guggenheim	Maintains	Buy → Buy	—	$23.32	$23.80	+2.1%	+1.1%	+0.5%	-0.6%	-7.9%	-8.4%
Sep 26	Wedbush	Maintains	Outperform → Outperform	—	$21.56	$21.43	-0.6%	+0.5%	-1.4%	+3.6%	+7.7%	+8.2%

Recent Filings

8-K

AnaptysBio, Inc. -- 8-K Filing

AnaptysBio's pro forma financials indicate a significant corporate transaction occurred, likely an acquisition or merger, requiring investors to review the combined entity's projected balance sheet and operations through December 31, 2025.

Apr 24

8-K

AnaptysBio, Inc. -- 8-K Filing

AnaptysBio completed a spin-off creating First Tracks Biotherapeutics, with detailed agreements governing asset transfers, liability assumptions, and ongoing relationships between the two independent entities.

Apr 20

8-K · 7.01 ! Medium

AnaptysBio, Inc. -- 8-K 7.01: Regulation FD Disclosure

AnaptysBio disclosed an investor presentation without material updates, suggesting the company is maintaining consistent messaging with stakeholders on its pipeline and strategic direction.

Mar 3

Data updated apr 24, 2026 6:05pm · Source: massive.com